Synereca Pharmaceuticals

Synereca Pharmaceuticals develops orally-active drugs that restore the effectiveness of existing antibiotics.

Synereca Pharmaceuticals, Inc. develops orally active drugs that restore the effectiveness of existing antibiotics. Its portfolio includes prototypic RecA inhibitors, which target various pathogenic bacteria/E. coli, including those responsible for lung, urinary tract, and skin infections, as well as weaponizable gram-positive and gram-negative pathogens through various bactericidal antibiotics. The company was incorporated in 2009 and is based in Chapel Hill, North Carolina.